XML 22 R5.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]        
Revenue [1]   $ 1,352,013,000 $ 907,957,000 $ 924,639,000
Expenses        
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) [1]   1,035,429,000 657,551,000 696,581,000
Selling, general and administrative expenses [1]   269,269,000 219,499,000 210,412,000
Depreciation and amortization expenses   67,195,000 60,037,000 60,835,000
Loss on disposal of assets and consolidation   0 0 698,000
Goodwill impairment   0 0 215,100,000
Change in fair value of contingent consideration   (23,522,000) 13,281,000 3,860,000
Total operating expenses $ 384,310,000 1,348,371,000 950,368,000 1,187,486,000
Operating income (loss)   3,642,000 (42,411,000) (262,847,000)
Interest income   1,369,000 407,000 2,633,000
Interest expense   (15,572,000) (25,425,000) (28,325,000)
Impairment of equity method investments   0 0 47,133,000
Gain from equity method investees   4,569,000 13,179,000 10,039,000
Gain on transfer of membership   0 45,938,000 0
Loss on extinguishment/repayment of debt   (10,192,000) (21,343,000) (4,789,000)
Change in tax receivable agreement liability   (45,950,000) 0 0
Other income (expense), net   57,000 (146,000) (118,000)
Loss from continuing operations before income taxes   (62,077,000) (29,801,000) (330,540,000)
Provision for (benefit from) income taxes   (43,376,000) 483,000 (2,368,000)
Loss from continuing operations   (18,701,000) (30,284,000) (328,172,000)
Loss from discontinued operations, net of tax [2]   (463,000) (7,317,000) (6,074,000)
Net loss attributable to common shareholders of Evolent Health, Inc - Basic (11,349,000) (19,164,000) (37,601,000) (334,246,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted $ (11,349,000) $ (19,164,000) $ (37,601,000) $ (334,246,000)
Basic and diluted:        
Continuing operations (in dollars per share) $ (0.11) $ (0.20) $ (0.35) $ (3.86)
Continuing operations (in dollars per share) (0.11) (0.20) (0.35) (3.86)
Discontinued operations (in dollars per share) 0 0 (0.09) (0.08)
Discontinued operations (in dollars per share) $ 0 0 (0.09) (0.08)
Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)   (0.20) (0.44) (3.94)
Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)   $ (0.20) $ (0.44) $ (3.94)
Weighted-average common shares outstanding        
Basic (in shares)   93,699 86,067 84,928
Diluted (in shares)   93,699 86,067 84,928
Comprehensive loss        
Net loss   $ (19,164,000) $ (37,601,000) $ (334,246,000)
Other comprehensive loss, net of taxes, related to:        
Foreign currency translation adjustment   (816,000) (84,000) (44,000)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.   $ (19,980,000) $ (37,685,000) $ (334,290,000)
[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.
[2] Includes $0.5 million and $6.8 million of loss on disposal of discontinued operations for years ended December 31, 2022 and 2021, respectively